Biotech | August 24, 2021
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The study was conducted in patients with mild to moderate COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The product patent has been already filed under fast track approval
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
Subscribe To Our Newsletter & Stay Updated
